Proactive Investors - Run By Investors For Investors

Seelos Therapeutics shares soar on acquisition of Parkinson's candidate license created at UCLA

Seelos Therapeutics Inc (NASDAQ:SEEL) CEO Dr. Raj Mehra tells Proactive Investors the company has acquired an exclusive license to the rights to a potential Parkinson’s disease therapy created by researchers at the University of California, Los Angeles.

Mehra said the therapy, known as SLS-007, may slow the progression of Parkinson's disease. He said the company may soon perform studies in mice.

Shares of the New York-based biotech rose more than 40% on Friday.

View full SEEL profile View Profile

Seelos Therapeutics Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use